Key result
Dehydromonocrotaline injection increases pulmonary medial wall thickness to 29% vs 7% in a canine model.
Why the study?
Quantification of in vivo pulmonary vascular remodeling in a large animal model of pulmonary hypertension was needed to better understand disease mechanisms.
Does a single injection of DHMC induce pulmonary vascular remodeling and pulmonary hypertension in young beagles?
Does a single injection of DHMC induce pulmonary vascular remodeling and pulmonary hypertension in young beagles?
A single injection of DHMC in young beagles provides a large animal model of pulmonary hypertension with vascular remodeling features similar to human primary PH.
We quantified in vivo pulmonary vascular remodeling in a large animal model of pulmonary hypertension (PH). In group PH (n = 6), 3 mg/kg dehydromonocrotaline (DHMC) was administered to 12-week-old beagles via a right atrial injection. Eight weeks after DHMC in group PH, pulmonary artery pressure increased significantly (P < .05) from 18 +/- 2 mm Hg at baseline to 30 +/- 4 mm Hg. Medial wall thickness and medial wall area as a percentage of total vessel diameter or area was significantly higher (P < .05) in group PH (29 +/- 9% and 48 +/- 12%) than in a control group (n = 5) (7 +/- 1% and 14 +/- 1%). Neointimal proliferation was observed in 42% of pulmonary arterioles in the PH group but never in the control group. We conclude that a single injection of DHMC in young beagles, in addition to the development of moderate degrees of PH after 8 weeks, causes significant pulmonary vascular remodeling, with features similar to those observed in patients with primary PH.
No takes yet. Share an insight, caveat, or question.
Daniel P. Schuster (2001) studied Pulmonary hypertension (n=11). Dehydromonocrotaline (DHMC) vs. Control group was evaluated on Medial wall thickness as a percentage of total vessel diameter (p=< .05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: